OrthoPediatrics Corp. (KIDS) Revenue History
Annual and quarterly revenue from 2014 to present
KIDS Revenue Over Time (2014–2025)
KIDS Revenue Growth History
10 of 11 years with positive growth- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- +30.9%
- FY2016 revenue growth
- +20.3%
- FY2017 revenue growth
- +22.3%
- FY2018 revenue growth
- +26.2%
- FY2019 revenue growth
- +26.0%
- FY2020 revenue growth
- -2.0%
- FY2021 revenue growth
- +37.9%
- FY2022 revenue growth
- +24.7%
- FY2023 revenue growth
- +21.6%
- FY2024 revenue growth
- +37.6%
- FY2025 revenue growth
- +15.4%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $59.4M | +13.3% |
| Q4 2025 | $61.6M | +17.0% |
| Q3 2025 | $61.3M | +12.2% |
| Q2 2025 | $61.1M | +15.7% |
| Q1 2025 | $52.4M | +17.3% |
| Q4 2024 | $52.7M | +40.0% |
| Q3 2024 | $54.6M | +36.5% |
| Q2 2024 | $52.8M | +33.5% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
KIDS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
KIDS Revenue Analysis (2014–2025)
Current Revenue & Growth
As of June 28, 2026, OrthoPediatrics Corp. (KIDS) generated trailing twelve-month (TTM) revenue of $243.3 million, reflecting strong growth of +13.3% year-over-year. The most recent quarter (Q1 2026) recorded $59.4 million in revenue, down 3.6% sequentially.
Historical Growth Trajectory
KIDS's 5-year compound annual growth rate (CAGR) stands at +27.2%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +24.6% is below the 5-year average, signalling a growth deceleration in recent years. OrthoPediatrics Corp.'s highest annual revenue of $236.3 million was recorded in 2025, an all-time high.
Revenue by Segment
KIDS's revenue is primarily driven by Trauma and Deformity (70%), Spine (28%), and Sports Medicine And Other (2%). With over half of revenue concentrated in Trauma and Deformity, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ATEC (-7.4% YoY), XTNT (-0.3% YoY), and GMED (+23.5% YoY) — KIDS has outperformed the peer group in revenue growth. Compare KIDS vs ATEC →
KIDS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KIDSCurrent | $243M | +13.3% | +27.2% | -12.3% | |
 ATEC | $764M | -7.4% | +39.5% | -10.7% | |
 XTNT | $134M | -0.3% | +20.2% | 5.4% | |
 GMED | $2.9B | +23.5% | +30.1% | 16.3% | |
 ZBH | $8.2B | +9.2% | +6.1% | 16.5% | |
 SYK | $25.1B | +8.8% | +11.8% | 19.5% |
KIDS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $236.3M | +15.4% | $172.7M | 73.1% | $-28,999,000 | -12.3% |
| 2024 | $204.7M | +37.6% | $148.6M | 72.6% | $-29,521,000 | -14.4% |
| 2023 | $148.7M | +21.6% | $111.3M | 74.8% | $-26,751,000 | -18.0% |
| 2022 | $122.3M | +24.7% | $90.7M | 74.1% | $-25,399,000 | -20.8% |
| 2021 | $98.0M | +37.9% | $73.4M | 74.9% | $-18,024,000 | -18.4% |
| 2020 | $71.1M | -2.0% | $55.0M | 77.4% | $-26,755,000 | -37.6% |
| 2019 | $72.6M | +26.0% | $54.6M | 75.3% | $-9,077,000 | -12.5% |
| 2018 | $57.6M | +26.2% | $42.7M | 74.2% | $-9,553,000 | -16.6% |
| 2017 | $45.6M | +22.3% | $34.5M | 75.5% | $-6,472,000 | -14.2% |
| 2016 | $37.3M | +20.3% | $26.4M | 70.7% | $-6,127,000 | -16.4% |
| 2015 | $31.0M | +30.9% | $21.6M | 69.8% | $-6,592,000 | -21.3% |
| 2014 | $23.7M | - | $16.6M | 70.1% | $-7,144,000 | -30.2% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KIDS — Frequently Asked Questions
Quick answers to the most common questions about buying KIDS stock.
Is KIDS's revenue growth accelerating or slowing?
KIDS revenue growth is holding steady at +13.3% year-over-year. TTM revenue is $243M. The current growth rate closely tracks the 5-year CAGR of +27.2%, signalling consistent execution.
What is KIDS's revenue history from 2014 to 2026?
OrthoPediatrics Corp. (KIDS) revenue history spans 2014 to 2026. TTM revenue as of 2026 is $243M, growing at +13.3% YoY. The 5-year CAGR is +27.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is KIDS's long-term revenue growth rate (CAGR)?
OrthoPediatrics Corp.'s 5-year revenue CAGR of +27.2% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +13.3% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for KIDS.
Why does KIDS's quarterly revenue fluctuate?
KIDS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. OrthoPediatrics Corp.'s revenue data from 2014 to 2026 shows full historical quarterly detail on this page.
How is KIDS's revenue distributed by segment?
KIDS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does KIDS's revenue compare to industry peers?
OrthoPediatrics Corp. (KIDS) with TTM revenue of $243M and +13.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.